Fibronostics is a global diagnostics company, providing non-invasive, algorithmic diagnostics and insights to detect and manage organ lesions caused by metabolic diseases. The company leverages artificial intelligence to screen and measure the progression and prognosis of liver & kidney disease as well as other chronic conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/24/20 | $8,000,000 | Series A |
AT Capital Elev8.vc | undisclosed |
